HONG KONG, China I June 3, 2025 I Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral ...

BASEL, Switzerland I June 04, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for ...

SAN DIEGO, CA, USA I June 03, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma ...

WHIPPANY, NJ, USA I June 03, 2025 I Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor ...

SOUTH SAN FRANCISCO, CA, USA I June 03, 2025 I TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to ...

Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian ...

LUND, Sweden and INDIANAPOLIS, IN, USA I June 3, 2025 I Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and ...

LUXEMBOURG & LEIDEN, The Netherlands I June 03, 2025 I The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden ...

NANTES, France I June 2, 2025 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” ...

NEW YORK, NY, USA I June 02, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions ...